Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Matthias Boentert. (2019) Sleep disturbances in patients with amyotrophic lateral sclerosis: current perspectives. Nature and Science of Sleep 11, pages 97-111.
Read now
Read now
. (2019) Theme 9 Clinical trials and trial design. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 20:sup1, pages 262-288.
Read now
Read now
Hiide Yoshino. (2019) Edaravone for the treatment of amyotrophic lateral sclerosis. Expert Review of Neurotherapeutics 19:3, pages 185-193.
Read now
Read now
Nicholas J. Maragakis. (2017) What can we learn from the edaravone development program for ALS?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 98-103.
Read now
Read now
Koji Takei, Kikumi Tsuda, Fumihiro Takahashi, Manabu Hirai & Joseph Palumbo. (2017) An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 88-97.
Read now
Read now
Articles from other publishers (16)
Hidetoshi Shimizu, Yukiko Nishimura, Youichi Shiide, Makoto Akimoto, Makiko Yashiro, Masaki Ueda, Manabu Hirai, Hiide Yoshino, Tomohiko Mizutani, Kazuaki Kanai, Osamu Kano, Hideki Kimura, Hisakuni Sekino & Kimiko Ito. (2023) Pharmacokinetics of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis. Clinical Therapeutics.
Crossref
Crossref
Mustafa Altinkaynak, Gokhan Kerim Gok, Bahar Ozmen, Serpil Buyukdemir, Timur Selcuk Akpinar, Sebile Nilgun Erten & Bulent Saka. (2023) Prognostic Value of Regular Nutritional Treatment in Patients With Amyotrophic Lateral Sclerosis. The Neurologist 28:3, pages 166-172.
Crossref
Crossref
Benjamin Rix Brooks, Terry Heiman-Patterson, Martina Wiedau-Pazos, Shawn Liu, Jeffrey Zhang & Stephen Apple. (2022) Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]. PLOS ONE 17:6, pages e0258614.
Crossref
Crossref
Anushruti Ashok, Syed Suhail Andrabi, Saffar Mansoor, Youzhi Kuang, Brian K. Kwon & Vinod Labhasetwar. (2022) Antioxidant Therapy in Oxidative Stress-Induced Neurodegenerative Diseases: Role of Nanoparticle-Based Drug Delivery Systems in Clinical Translation. Antioxidants 11:2, pages 408.
Crossref
Crossref
Benjamin Rix Brooks, Erik P. Pioro, Jonathan Katz, Fumihiro Takahashi, Koji Takei, Jeffrey Zhang & Stephen Apple. (2021)
Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: Post hoc analysis of
ALSFRS‐R
item scores in pivotal study
MCI186
‐19
. Muscle & Nerve 65:2, pages 180-186.
Crossref
Crossref
Pasha Apontes. 2022. TDP-43 and Neurodegeneration. TDP-43 and Neurodegeneration
183
250
.
Sweta Shah, Marc Marie Dooms, Sofia Amaral-Garcia & Mariana Igoillo-Esteve. (2021) Current Drug Repurposing Strategies for Rare Neurodegenerative Disorders. Frontiers in Pharmacology 12.
Crossref
Crossref
Hidetoshi Shimizu, Yukiko Nishimura, Youichi Shiide, Kaori Yoshida, Manabu Hirai, Munetomo Matsuda, Yoshinobu Nakamaru, Yuichiro Kato & Kazuoki Kondo. (2021) Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects. Clinical Pharmacology in Drug Development 10:10, pages 1188-1197.
Crossref
Crossref
Hidetoshi Shimizu, Yukiko Nishimura, Yoichi Shiide, Hideaki Matsuda, Makoto Akimoto, Munetomo Matsuda, Yoshinobu Nakamaru, Yuichiro Kato & Kazuoki Kondo. (2021) Evaluation of Pharmacokinetics, Safety, and Drug‐Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults. Clinical Pharmacology in Drug Development 10:10, pages 1174-1187.
Crossref
Crossref
Jessica R. Morrice, Michael Kuo & Christopher A. Shaw. 2021. Spectrums of Amyotrophic Lateral Sclerosis. Spectrums of Amyotrophic Lateral Sclerosis
181
199
.
Cyril Jones Jagaraj, Sonam Parakh & Julie D. Atkin. (2021) Emerging Evidence Highlighting the Importance of Redox Dysregulation in the Pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Frontiers in Cellular Neuroscience 14.
Crossref
Crossref
Juan Fernando Ortiz, Sawleha Arshi Khan, Amr Salem, Zayar Lin, Zafar Iqbal & Nusrat Jahan. (2020) Post-Marketing Experience of Edaravone in Amyotrophic Lateral Sclerosis: A Clinical Perspective and Comparison With the Clinical Trials of the Drug. Cureus.
Crossref
Crossref
Matthias Boentert. (2020) Sleep and Sleep Disruption in Amyotrophic Lateral Sclerosis. Current Neurology and Neuroscience Reports 20:7.
Crossref
Crossref
Adriano Chiò, Letizia Mazzini & Gabriele Mora. (2020) Disease-modifying therapies in amyotrophic lateral sclerosis. Neuropharmacology 167, pages 107986.
Crossref
Crossref
Jin-Mo Park, Sun-Young Kim, Donghwi Park & Jin-Sung Park. (2019) Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients. Neurological Sciences 41:1, pages 119-123.
Crossref
Crossref
Magdalena Kuźma-Kozakiewicz. (2018) Edaravone in the treatment of amyotrophic lateral sclerosis. Neurologia i Neurochirurgia Polska 52:2, pages 124-128.
Crossref
Crossref